MedPath

Tavaborole

Tavaborole Topical Solution These highlights do not include all the information needed to use TAVABOROLE TOPICAL SOLUTION safely and effectively. See full prescribing information for TAVABOROLE TOPICAL SOLUTION. TAVABOROLE topical solution Initial U.S. Approval: 2014

Approved
Approval ID

7fe75d38-80a0-444e-84bc-4087b45a791e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 15, 2023

Manufacturers
FDA

Chartwell RX, LLC

DUNS: 079394054

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Tavaborole

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code62135-663
Application NumberANDA211963
Product Classification
M
Marketing Category
C73584
G
Generic Name
Tavaborole
Product Specifications
Route of AdministrationTOPICAL
Effective DateSeptember 15, 2023
FDA Product Classification

INGREDIENTS (5)

ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGF
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
TAVABOROLEActive
Quantity: 43.5 mg in 1 mL
Code: K124A4EUQ3
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tavaborole - FDA Drug Approval Details